Table 1

Patient demographics

Patient no.Age at diagnosis, y/sexDiagnosisCytogeneticsTreatmentDay of WBC nadirWBC nadir, cells/mm3*Day of leukocyte recoveryPrevious chemotherapy or radiation exposureAchievement of CR/CR durationMortality at 2 y/cause of death
1 51/M AML/MDS 45 XY, −7 AcDVP16 16 80 18 Azacitidine, hydroxyurea, and lenalidomide for MDS No Deceased/persistent disease 
2 40/M AML/MDS 44–45 XY, complex AcDVP16 12 80 17 Pelvic irradiation for anaplastic testicular seminoma in 1998; azacitidine, MS-275, and lenalidomide for MDS No Deceased/persistent disease 
3 64/F AML/MDS 46 XX, FLT3-ITD+ FLAM 10 50 12  Yes/5 mo Deceased/sepsis and cardiac arrhythmia 
4 42/M AML de novo 46 XY, t(11;19) FLAM 18 210 26  Yes/> 24 mo with transplantation at 2 mo Alive 
5 61/M AML de novo 46 XY FLAM 25 280 27  Yes/> 24 mo Alive 
6 69/M AML de novo 46 XY AcDVP16 16 150 18  Yes/15 mo Deceased/toxicity from chemotherapy for relapsed disease 
7 22/M AML de novo 46 XY AcDVP16 15 620 18  No Deceased/persistent disease 
8 59/M AML/MDS 46 XY FLAM 14 420 17  Yes/>24 mo Alive 
9 70/M AML/MDS 46 XY FLAM 10 420 22  Yes/13 months Alive 
10 42/F AML secondary to breast cancer treatment 46 XX, t(9;11) AcDVP16 11 < 50 20 Cyclophosphamide, doxorubicin, paclitaxel, trastuzumab, and tamoxifen for breast cancer; cyclophosphamide for cytoreduction before induction TST Yes/>24 mo with transplantation at 15 mo Alive 
11 30/F AML de novo 46 XX AcDVP16 10 70 12  Yes/9 mo Deceased/persistent disease 
12 67/M AML secondary to CLL treatment 43 XY, complex FLAM 16 280 26 Cyclophosphamide, rituximab, and fludarabine for 6 cycles for CLL No Deceased/persistent disease 
13 47/F AML de novo 46 XX, inv(16) AcDVP16 15 90 18  Yes/> 24 mo Alive 
14 58/M AML/MDS 48 XY, +8, +21 FLAM 16 230 24  Yes/> 24 mo with transplantation at 3 mo Alive 
15 23/F AML de novo 46 XX, t(8;8) AcDVP16 17 230 22  Yes/2 mo Deceased/fungal pneumonia during treatment of relapsed disease 
16 54/M AML de novo 46 XY AcDVP16 8 <50 19 Cyclophosphamide for cytoreduction before induction TST Yes/> 24 mo Alive 
17 67/M AML de novo 46XY, t(8;21), FLT3-ITD+ FLAM 21 140 29  Yes/4 mo Deceased/persistent disease 
18 43/F AML/MDS 46 XX AcDVP16 11 460 17  No Deceased/staphylococcal sepsis during induction TST 
19 62/M AML de novo 46 XY FLAM 9 210 15  Yes/17 mo Alive 
20 48/M AML de novo 46 XY AcDVP16 8 160 17  Yes/> 24 mo Alive 
Patient no.Age at diagnosis, y/sexDiagnosisCytogeneticsTreatmentDay of WBC nadirWBC nadir, cells/mm3*Day of leukocyte recoveryPrevious chemotherapy or radiation exposureAchievement of CR/CR durationMortality at 2 y/cause of death
1 51/M AML/MDS 45 XY, −7 AcDVP16 16 80 18 Azacitidine, hydroxyurea, and lenalidomide for MDS No Deceased/persistent disease 
2 40/M AML/MDS 44–45 XY, complex AcDVP16 12 80 17 Pelvic irradiation for anaplastic testicular seminoma in 1998; azacitidine, MS-275, and lenalidomide for MDS No Deceased/persistent disease 
3 64/F AML/MDS 46 XX, FLT3-ITD+ FLAM 10 50 12  Yes/5 mo Deceased/sepsis and cardiac arrhythmia 
4 42/M AML de novo 46 XY, t(11;19) FLAM 18 210 26  Yes/> 24 mo with transplantation at 2 mo Alive 
5 61/M AML de novo 46 XY FLAM 25 280 27  Yes/> 24 mo Alive 
6 69/M AML de novo 46 XY AcDVP16 16 150 18  Yes/15 mo Deceased/toxicity from chemotherapy for relapsed disease 
7 22/M AML de novo 46 XY AcDVP16 15 620 18  No Deceased/persistent disease 
8 59/M AML/MDS 46 XY FLAM 14 420 17  Yes/>24 mo Alive 
9 70/M AML/MDS 46 XY FLAM 10 420 22  Yes/13 months Alive 
10 42/F AML secondary to breast cancer treatment 46 XX, t(9;11) AcDVP16 11 < 50 20 Cyclophosphamide, doxorubicin, paclitaxel, trastuzumab, and tamoxifen for breast cancer; cyclophosphamide for cytoreduction before induction TST Yes/>24 mo with transplantation at 15 mo Alive 
11 30/F AML de novo 46 XX AcDVP16 10 70 12  Yes/9 mo Deceased/persistent disease 
12 67/M AML secondary to CLL treatment 43 XY, complex FLAM 16 280 26 Cyclophosphamide, rituximab, and fludarabine for 6 cycles for CLL No Deceased/persistent disease 
13 47/F AML de novo 46 XX, inv(16) AcDVP16 15 90 18  Yes/> 24 mo Alive 
14 58/M AML/MDS 48 XY, +8, +21 FLAM 16 230 24  Yes/> 24 mo with transplantation at 3 mo Alive 
15 23/F AML de novo 46 XX, t(8;8) AcDVP16 17 230 22  Yes/2 mo Deceased/fungal pneumonia during treatment of relapsed disease 
16 54/M AML de novo 46 XY AcDVP16 8 <50 19 Cyclophosphamide for cytoreduction before induction TST Yes/> 24 mo Alive 
17 67/M AML de novo 46XY, t(8;21), FLT3-ITD+ FLAM 21 140 29  Yes/4 mo Deceased/persistent disease 
18 43/F AML/MDS 46 XX AcDVP16 11 460 17  No Deceased/staphylococcal sepsis during induction TST 
19 62/M AML de novo 46 XY FLAM 9 210 15  Yes/17 mo Alive 
20 48/M AML de novo 46 XY AcDVP16 8 160 17  Yes/> 24 mo Alive 

WBC indicates white blood cell; MDS, myelodysplastic syndrome; ITD, internal tandem duplication; and CLL, chronic lymphocytic leukemia.

*

To convert mm3 to × 109/L, multiply by 0.001.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal